Meeting
2022 ASCO Annual Meeting
Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.
Authors
Phuoc T. Tran
University of Maryland School of Medicine, Baltimore, MD
Phuoc T. Tran , Kathryn Lowe , Hao Wang , Hua-Ling Tsai , Daniel Y. Song , Arthur Hung , Jason W.D. Hearn , Tamara L. Lotan , Channing Judith Paller , Mark Christopher Markowski , Samuel R. Denmeade , Michael Anthony Carducci , Mario A. Eisenberger , Matthew Orton , Curtiland Deville , Stanley L. Liauw , Elisabeth I. Heath , Neil B Desai , Tomasz M. Beer , Emmanuel S. Antonarakis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT02203695
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5012)
DOI
10.1200/JCO.2022.40.16_suppl.5012
Abstract #
5012
Poster Bd #
196
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2021 Genitourinary Cancers Symposium
Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2019 ASCO Annual Meeting
A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).
First Author: Tian Zhang
Poster
2019 Genitourinary Cancers Symposium
Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.
First Author: Andrew J. Armstrong